Zhejiang Yatai Pharmaceutical Third Quarter 2024 Earnings: CN¥0.012 loss per share (vs CN¥0.028 loss in 3Q 2023)
Zhejiang Yatai Pharmaceutical (SZSE:002370) Third Quarter 2024 Results
Key Financial Results
- Revenue: CN¥84.9m (up 5.2% from 3Q 2023).
- Net loss: CN¥8.93m (loss narrowed by 52% from 3Q 2023).
- CN¥0.012 loss per share (improved from CN¥0.028 loss in 3Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Zhejiang Yatai Pharmaceutical shares are up 2.8% from a week ago.
Risk Analysis
It's still necessary to consider the ever-present spectre of investment risk. We've identified 1 warning sign with Zhejiang Yatai Pharmaceutical, and understanding it should be part of your investment process.
Valuation is complex, but we're here to simplify it.
Discover if Zhejiang Yatai Pharmaceutical might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About SZSE:002370
Zhejiang Yatai Pharmaceutical
Researches, produces, sells, and exports pharmaceutical products in China and internationally.
Excellent balance sheet and slightly overvalued.
